Pressure Biosciences Inc (OTCQB: PBIO), the life sciences sector sample preparation firm, said its next-generation PCT (pressure cycling technology) instrument - the Barocycler 2320EXTREME - was selected as a finalist in the prestigious R&D 100 Awards for 2017.
Finalists were chosen by an independent panel of more than 50 judges, based on each product's impact potential, uniqueness, and technical capabilities, said the firm.
This year's winners will be announced at a ceremony on November 17 this year.
ProCan, a cancer research initiative in Australia and the first international collaborator of the US Cancer Moonshot program, purchased three of the products last year
Professor Phil Robinson, co-director, said: "We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. The goal is to diagnose each individual patients' cancer to make more rapid and accurate predictions of the best cancer treatment to use -- or to avoid -- for that individual. This will also advance scientific discovery for new drug targets."
He added: "Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, a project like ProCan simply could not be done."
Shares added 3.24% to US$4.14